-
1 Comment
TalkMed Group Limited is currently in a long term downtrend where the price is trading 4.3% below its 200 day moving average.
From a valuation standpoint, the stock is 1.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 8.6.
TalkMed Group Limited's total revenue sank by 36.1% to $14M since the same quarter in the previous year.
Its net income has dropped by 55.3% to $5M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.0% to $6M since the same quarter in the previous year.
Based on the above factors, TalkMed Group Limited gets an overall score of 1/5.
| Exchange | SG |
|---|---|
| CurrencyCode | SGD |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| ISIN | SG2G61000003 |
| Market Cap | 585M |
|---|---|
| PE Ratio | 14.67 |
| Target Price | 0.66 |
| Dividend Yield | 5.0% |
| Beta | 0.02 |
TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. It operates through two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia. It also provides palliative care services comprising cancer pain management, discharge and home care planning, advance care planning, and end-of-life care planning; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. In addition, the company offers goods and services related to cellular and gene therapy; specialist doctors and clinical staff services; and healthcare management services. Further, the company develops novel processing platforms for cell and gene therapy and carrying out research in genetic modification of immune cells; and novel platform viral vector technologies that strive to advance genetic modification of cellular therapy through basic vector system design. TalkMed Group Limited was founded in 1997 and is based in Singapore. The company operates as a subsidiary of Citibank Nominees Singapore Pte Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 5G3.SG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
